Cholesterol biosynthesis as a drug-induced vulnerability in diffuse large B cell lymphoma insensitive to EZH2 inhibition

•GCB-DLBCL insensitive to EZH2 inhibition become dependent on cholesterol synthesis.•This dependency relates to altered LDLR subcellular localization and LDL uptake.•EZH2 inhibition attenuates activation of SREBP2 targets. The methyltransferase EZH2 is a critical epigenetic writer in Germinal Center...

Full description

Saved in:

Bibliographic Details
Published in:	Neoplasia (New York, N.Y.) Vol. 70; p. 101243
Main Authors:	Niccolai, Rachele, Göbel, Camiel, Ndoj, Klevis, Kreft, Maaike, Kuiken, Hendrik J., Lieftink, Cor, Morris, Ben, Yska, Sietse D., Hendrix, Sebastian, van den Broek, Bram, Pappalardo, Vincent, Kersten, Marie José, Beijersbergen, Roderick L., Zelcer, Noam, van Leeuwen, Fred, Jacobs, Heinz
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.12.2025 Elsevier
Subjects:	Animals Antineoplastic Agents - pharmacology Cell Line, Tumor Cholesterol - biosynthesis CRISPR-Cas9 screen Diffuse large B cell lymphoma Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors Enhancer of Zeste Homolog 2 Protein - genetics Enhancer of Zeste Homolog 2 Protein - metabolism EZH2 Humans LDL-receptor Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - metabolism Lymphoma, Large B-Cell, Diffuse - pathology Mice Oncology Receptors, LDL - metabolism Xenograft Model Antitumor Assays Diffuse large B cell lymphoma Cholesterol Biosynthesis LDL-receptor CRISPR-Cas9 screen EZH2
ISSN:	1476-5586, 1476-5586
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!